Navigation Links
Drug Discovery in Rare Diseases
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Drug Discovery in Rare Diseases

http://www.reportlinker.com/p0968548/Drug-Discovery-in-Rare-Diseases.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

 

In comparison with major diseases, the targeting of rare diseases poses many different challenges, necessitating consideration of bespoke R&D strategies for drug discovery efforts to be successful. This report examines the role that low disease prevalence plays in determining the most suitable R&D path.Understand the growing interest in developing new treatments for rare diseases, and why low patient numbers do not preclude commercial viability.Review the regulatory environment governing the development of orphan drugs in different countries.Identify the key challenges that are presented by low patient prevalences.Assess how the research strategy chosen can be influenced by the disease prevalence.Compare the scenarios in which repurposing of existing drugs offers advantages over the development of novel drugs, and vice versa.Approximately 7,000 rare diseases have been identified, but only a very small proportion of these are currently well treated. Orphans represent a greater proportion of all new BLAs than they do of NMEs submitted as NDAs. Most orphan approvals are not first approvals of new drugs but are new orphan indications for previously approved drugs.It is possible to obtain orphan drug designation for conditions with a total prevalence greater than that defined by legislation, but only if medically justifiable subsets can be defined with a lower (overall) prevalence. Pediatric subsets are most commonly used.In the development of new treatments for rare diseases it is less critical to seek to optimize the pharmacokinetic properties of candidates than is the case for common chronic diseases, with parenteral delivery or frequent oral dosing being much more acceptable provided that efficacy is achieved.What impact on R&D strategy does disease prevalence have on moving from rare through very rare to ultra rare diseases?Can more than one drug be a commercial success for treating rare indications, and how do drug regulators view the question of drug similarity?What are the best ways of identifying patients for recruitment into clinical trials for drugs designed to treat rare diseases?What are the requirements for a clinical candidate to treat a rare disease?What factors determine whether a small-molecule or biologic strategy is most suitable when targeting a rare disease?

 

 

 

EXECUTIVE SUMMARY•Key findings

 

The growing interest in rare diseases•Summary

•Introduction

•What is a rare disease?

•Why target rare diseases?

 

Characterization of rare diseases•Summary

•Overview

•Rare diseases

•Very rare diseases

•Ultra rare diseases

•Useful resources

 

Orphan drug status•Summary

•Introduction

•Legislative distinctions - US

- Europe

- Japan

- Other markets

 

•Tax benefits

•Patient population subsetting

•Similarity

•Summary of key considerations

 

Choosing rare diseases to target•Summary

•Introduction

•Key issues

•Commercial potential - Prevalence

- Geographic distribution

- Disease understanding

- Available experts

- Current treatments

- What is similar?

 

•Conclusion

 

Preclinical development•Summary

•Introduction

•Screen or repurpose? - Repurposed

- Directed approaches

- Taking advantage of orphan drug status

 

•Other issues - Small molecule or biological?

- Biological test models

- Requirements of a clinical candidate

 

•Conclusions

 

Clinical issues•Summary

•Introduction

•Clinical trial design

•Access to patients - Geographic distribution

- Identifying patients

 

•Conclusions

 

Commercial considerations•Summary

•Introduction

•Identifying commercially promising opportunities - Prevalence

- Current treatments

- Competitive position

 

•Case studies - (Untitled sub-section)

- Gaucher disease

 

•Conclusions

 

Conclusions•Summary

•Introduction

•Checklist to consider

•Corporate strategies

•Conclusions

 

Appendix•Scope

•Methodology

•Glossary/abbreviations

•Bibliography/references

 

 

TABLES

•Table: Timeline of international orphan drug legislation, 1983–2008

•Table: Comparison of orphan drug legislation in the US, Europe, and Japan

•Table: The FDA's definitions of similarity

 

 

FIGURES

•Figure: US FDA orphan approvals, 2001–11 (part 1)

•Figure: US FDA orphan approvals, 2001–11 (part 2)

•Figure: Rare diseases, medical need, and disease prevalence

•Figure: Distribution of US orphan drug approvals by disease prevalence (to 2010)

•Figure: European orphan drug approvals by disease prevalence (to 2010)

•Figure: Exploiting knowledge resources for rare disease research

•Figure: The organizational relationships within the EMA pertaining to orphan drugs

•Figure: Schematic relationship between rare disease prevalence and commercial returns

•Figure: Identifying suitable patients for clinical studies

•Figure: The influence of prevalence on research strategy

•Figure: Current exploitation of rare disease space

•Figure: "Similar" approved BCR-ABL inhibitors with orphan drug status

•Figure: Similar approved endothelin receptor antagonists with orphan drug status

•Figure: Selecting a rare disease to target

•Figure: Alternative strategies to identifying new treatments for rare diseases

•Figure: Strategic pathways for identifying development candidates

•Figure: Comparison of duration and size of clinical studies in developing drugs to treat major diseases (a), and rare diseases (b)

•Figure: Number of participants in European orphan drug clinical trials

•Figure: Comparing commercial opportunities

•Figure: Strategic options for developing drugs for already targeted rare diseases

•Figure: Different approaches to treating cystic fibrosis

•Figure: GlaxoSmithKline and Pfizer; exploiting internal and external resources in rare disease research

 

 

 

Companies Mentioned

Amlin plc, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Recordati S.p.A., Sanofi, WPP Group plc

 

 

 

To order this report:

Drug_Discovery_and_Development Industry: Drug Discovery in Rare Diseases

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Initiating Rare Disease Drug Discovery Projects
3. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
4. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
5. Drug Discovery Technologies, BCC Research
6. Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
9. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
10. Omeros Announces Discovery in MASP-2 Program
11. Discovery Labs Receives US Patent for Method to Promote Mucus Clearance with Pulmonary Surfactant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group ... Tournament held on June 20th at the Woodmont Country Club at 1201 Rockville ... an organization dedicated to helping service members that have been wounded in battle and ...
Breaking Medicine News(10 mins):